Patents by Inventor Sreekantha Ratna Kumar
Sreekantha Ratna Kumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124489Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X, Y, A, G, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: ApplicationFiled: September 30, 2020Publication date: April 18, 2024Inventors: Sreekantha Ratna Kumar, Lazman Pasunoori, Subramanya Hegde, Anupama Kandhi, Durga Buchi Paju Barre, Alaric J. Dyckman
-
Patent number: 11912703Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: June 30, 2022Date of Patent: February 27, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Sreekantha Ratna Kumar, Durga Buchi Raju Barre, Srinivasan Kunchithapatham Duraisamy
-
Patent number: 11878975Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: December 18, 2018Date of Patent: January 23, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, John L. Gilmore, Tasir Shamsul Haque, Trevor C. Sherwood, Brian K. Whiteley, Shoshana L. Posy, Sreekantha Ratna Kumar, Laxman Pasunoori, Srinivasan Kunchithapatham Duraisamy, Subramanya Hegde, Rushith Kumar Anumula, Pitani Veera Venkata Srinivas
-
Patent number: 11820768Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: April 30, 2021Date of Patent: November 21, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, Brian K. Whiteley, John L. Gilmore, Sreekantha Ratna Kumar, Laxman Pasunoori, Pitani Veera Venkata Srinivas, Srinivasan Kunchithapatham Duraisamy, Subramanya Hegde, Rushith Kumar Anumula
-
Patent number: 11739098Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: March 21, 2022Date of Patent: August 29, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, John L. Gilmore, Tasir Shamsul Haque, Brian K. Whiteley, David R. Tortolani, Shoshana L. Posy, John E. Macor, Louis J. Lombardo, Ramesh Kumar Sistla, Anupama Kandhi Ramachandra Reddy, Subramanya Hegde, Laxman Pasunoori, Sreekantha Ratna Kumar
-
Publication number: 20230255941Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: ApplicationFiled: April 26, 2023Publication date: August 17, 2023Inventors: Alaric J. DYCKMAN, Dharmpal S. Dodd, Tasir Shamsul Haque, Louis J. Lombardo, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Shoshana L. Posy, Ramesh Kumar Sistla, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy
-
Patent number: 11672780Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: December 7, 2020Date of Patent: June 13, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Haque, Louis J. Lombardo, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Shoshana L. Posy, Ramesh Kumar Sistla, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy
-
Publication number: 20230117470Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: ApplicationFiled: October 30, 2020Publication date: April 20, 2023Inventors: Laxman Pasunoori, Sreekantha Ratna Kumar, Pitani Veera Venkata Srinivas, Vikram Bhogadi, Duraisamy Kunchithapatham Srinivasan, Anupama Kandhi Ramachandra Reddy, Rushith Kumar Anumula, Alaric J. Dyckman
-
Publication number: 20230098244Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: ApplicationFiled: March 21, 2022Publication date: March 30, 2023Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, John L. Gilmore, Tsair Shamsul Haque, Brian K. Whiteley, David R. Tortolani, Shoshana L. Posy, John E. Macor, Louis J. Lombardo, Ramesh Kumar Sistla, Anupama Kandhi Ramachandra Reddy, Subramanya Hegde, Laxman Pasunoori, Sreekantha Ratna Kumar
-
Publication number: 20220348576Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: ApplicationFiled: June 30, 2022Publication date: November 3, 2022Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Sreekantha Ratna Kumar, Durga Buchi Raju Barre, Srinivasan Kunchithapatham Duraisamy
-
Publication number: 20220340555Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: ApplicationFiled: April 30, 2021Publication date: October 27, 2022Inventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, Brian K. Whiteley, John L. Gilmore, Sreekantha Ratna Kumar, Laxman Pasunoori, Pitani Veera Venkata Srinivas, Srinivasan Kunchithapatham Duraisamy, Subramanya Hegde, Rushith Kumar Anumula
-
Publication number: 20220289739Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: ApplicationFiled: May 7, 2020Publication date: September 15, 2022Inventors: Alaric J. DYCKMAN, Laxman Pasunoori, Sreekantha Ratna Kumar, Srinivasan Kunchithaptham Duraisamy, Pitani Veera Venkata Srinivas, Vikram Bhogadi, Subramanya Hegde
-
Patent number: 11427580Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: December 18, 2018Date of Patent: August 30, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Sreekantha Ratna Kumar, Durga Buchi Raju Barre, Srinivasan Kunchithapatham Duraisamy
-
Patent number: 11420958Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: December 19, 2018Date of Patent: August 23, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Christopher P. Mussari, Tasir Shamsul Haque, Brian K. Whiteley, Shoshana L. Posy, Sreekantha Ratna Kumar, Laxman Pasunoori, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy, Rushith Kumar Anumula
-
Patent number: 11420973Abstract: N-oxides, or salts thereof, wherein G, L2, R1, R5, R9, R10, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: December 18, 2018Date of Patent: August 23, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, Tasir Shamsul Haque, Shoshana L. Posy, Sreekantha Ratna Kumar, Laxman Pasunoori, Subramanya Hegde, Rushith Kumar Anumula
-
Patent number: 11299501Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, X, Y, Z, R1, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: December 18, 2018Date of Patent: April 12, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Brian K. Whiteley, Sreekantha Ratna Kumar, Anupama Kandhi Ramachandra Reddy
-
Patent number: 11180474Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: July 27, 2017Date of Patent: November 23, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Tasir S. Haque, Michael A. Poss, Louis J. Lombardo, John E. Macor, Laxman Pasunoori, Sreekantha Ratna Kumar
-
Patent number: RE49880Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: January 25, 2022Date of Patent: March 26, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Alaric J. Dyckman, Dharmpal S. Dodd, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Ramesh Kumar Sistla
-
Patent number: RE49893Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: January 25, 2022Date of Patent: April 2, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Hague, Louis J. Lombardo, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Shoshana L. Posy, Ramesh Kumar Sistla, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy
-
Patent number: RE49931Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: January 25, 2022Date of Patent: April 23, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar
